Nightbox LLC Initiates Provisional Patent Filing for Chimeric NKG2D-LIF6 Receptor-Effector Construct

Nightbox LLC has initiated provisional patent filing on the NKG2D-LIF6 chimeric receptor-effector construct, a 2,123 bp single-construct AAV9 gene therapy for solid tumor oncology.